Skip to main content
ASNDAscendis Pharma A/SBuy Wait7.0·$269.97-0.43%

Ascendis Pharma A/S (ASND) Q2 2026 earnings — TrendMatrix coverage

BEAT+17.4% vs estimateEPS $0.90 vs $0.77 estVerdict SellHold

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$0.90
Estimate
$0.77
Surprise
+17.4%
Score at report (before → after)
6.16.8/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Report record · Q2 2026

How the report landed

Ascendis Pharma A/S (ASND) beat the $0.77 estimate with diluted EPS of $0.90 — a large 17.4% upside surprise. TrendMatrix's engine moved from Sell (6.1/10) to Hold at 6.8/10 after the report.

Current read · as of 2026-09-04

Where TrendMatrix's rating stands now

TrendMatrix currently rates ASND Buy (Wait) at 7.0/10.

2 of the last 4 quarters beat the estimate; this quarter's +17.4% surprise compares with a +107.4% four-quarter average.

What supports the rating

  • V7 flight-to-quality bonus: +0.5 (Q=8.3 in RISK_OFF)
  • Sector modifier (Healthcare): +0.5

What argues against it

  • Thin upside margin: 5.2%
  • Near 52-week high (4.5% away)
  • RISK-OFF: MID-cap BUY_NOW needs quality>=8.5 or MoS>=50%

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$269.97
Entry target
$243.41
Price target
$283.47
Stop
$227.19
Upside to target
+5.0%
Reward-to-risk
0.5:1

Forward estimates sit below the trailing run-rate (28.7× forward vs 20.6× trailing) — consensus expects earnings to decline from here.

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare context

ASND at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Biotechnology
Market cap
$17.78B
P/E (fwd)
28.7
P/E (ttm)
20.6
52-week range
$186.05$282.15
Off 52-week high
4.3%
RSI (14)
69
Volume vs avg
0.73×
Score today
7.0/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks ASND Earnings Q2 2026 earnings